Maria Palasis - Oct 1, 2025 Form 4/A - Amendment Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role
President & CEO, Director
Signature
/s/ Jason Cavalier, Attorney-in-Fact for Maria Palasis, Ph.D.
Stock symbol
LYRA
Transactions as of
Oct 1, 2025
Transactions value $
$0
Form type
4/A - Amendment
Date filed
10/8/2025, 04:30 PM
Date Of Original Report
Oct 3, 2025
Previous filing
Jul 14, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Palasis Maria President & CEO, Director C/O LYRA THERAPEUTICS, INC., 480 ARSENAL WAY, WATERTOWN /s/ Jason Cavalier, Attorney-in-Fact for Maria Palasis, Ph.D. 2025-10-08 0001810701

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LYRA Employee Stock Option (right to buy) 0 Oct 1, 2025 Common Stock 0 $303.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 21, 2024, the Reporting Person was granted a performance stock option ("PSO") for an aggregate of up to 11,000 shares of common stock (or 550,000 shares on a pre-split basis) under the Issuer's 2020 Incentive Award Plan. On February 14, 2025, the PSOs were forfeited in their entirety by the Reporting Person for no value.

Remarks:

On October 3, 2025, a Form 4 was inadvertently filed reporting the acquisition of 3,667 PSOs by the Reporting Person. In fact, the Reporting Person did not acquire the PSOs and this Form 4/A is being filed to correct the erroneously reported acquisition. As of the date hereof, the Reporting Person does not beneficially own any of the PSOs granted on March 21, 2024.